TY - JOUR
T1 - Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma
AU - Lin, Adam Yuh
AU - Rink, Jonathan Scott
AU - Karmali, Reem
AU - Xu, Jiahui
AU - Kocherginsky, Masha
AU - Thaxton, Colby Shad
AU - Gordon, Leo I.
N1 - Funding Information:
Funding Sources: This work was supported by the Robert H. Lurie Comprehensive Cancer Center Cancer Center (RHLCCC) Support Grant ( NCI CA060553 ). AYL was supported by the American Society of Hematology Research Training Award for Fellows and the Northwestern University's Physician Scientist Training Program . LIG was supported by the RHLCCC Support Grant, Shannahan, Brookstone and Mander Foundations . This work was also supported by the Northwestern University RHLCCC Flow Cytometry Facility , and the Quantitative Data Sciences Core .
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.
AB - CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.
KW - Apoptosis
KW - CpG oligodeoxynucleotides
KW - Lymphoma therapy
KW - Nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85090548735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090548735&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2020.102290
DO - 10.1016/j.nano.2020.102290
M3 - Article
C2 - 32798731
AN - SCOPUS:85090548735
SN - 1549-9634
VL - 30
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
M1 - 102290
ER -